Reagent Dispense History

ID	Lot	Project	Requestor	Requested	Purpose	Delivered	Dispenser	Amt(mg)	
83	A-765865.	0 D2E7							
	1311710	ANTI-TNF ALPHA	PEREILX	01/26/2006	Large-scale F(ab) generation	02/10/2006	PEREILX	20	
	1311710	ANTI-TNF ALPHA	TARCSEX	03/06/2006	Humira Inhalation study PK analysis	03/07/2006	PEREILX	1	
	1311710	ANTI-TNF ALPHA	BAJARAC	12/12/2005	IL-1ab	12/13/2005	PEREILX	0.677 21.677	
45	A-796147.0 125-2H mu lgG1								
	1276664	ANTI IL-18 MAB	BRYANSH	12/22/2005	CIA-137 combo	01/03/2006	GIFFOKA	28	
	1276664	ANTI IL-18 MAB	GOESSCA	01/06/2006	Control reagent for anti-CXCL13 MAB studies	01/12/2006	PEREILX	10	
								38	
119	A-796874.	0 J695							
	1313235	ANTI IL-12 (BD ILS999)	WISCHEM	02/17/2006		02/15/2006	GIFFOKA	0.5	
	1313235	ANTI IL-12 (BD ILS999)	GIFFOKA	12/05/2005	IL-23 BioAssay, per Erik M Wischhof	12/06/2005	GIFFOKA	0.5	
								1	
39	A-799538.	•							
	1330424	ANTI-TNF ALPHA	BAJARAC	12/12/2005	IL-1ab	12/13/2005	PEREILX	0.5	
								0.5	
44	A-803296.	•							
	1274240	ANTI IL-18 MAB		12/22/2005	CIA-138 combo	01/13/2006	GIFFOKA	28	
	1274240	ANTI IL-18 MAB	GIFFOKA	12/28/2005	LC-MS & SEC-HPLC for COT completion	01/04/2006	GIFFOKA	0.5	
76	A-834443.	0 9H10.C2.E2 mu lgG1/k	Cwt					28.5	
70	1227132	ANTI IL-1 ALPHA/BETA	MCCARD	01/17/2006		01/18/2006	PEREILX	20	
	1227132	ANTI IL-1 ALPHA/BETA	PEREILX	12/07/2005	CRO Study	12/07/2005	PEREILX	30	
					,			50	
112	A-835496.	0 murine TNFa-biotin							
	1282832	ANTI-TNF ALPHA	KALGHLK	02/08/2006	MSD assay development	02/08/2006	SWENSJT	0.1	
								0.1	
55	A-846166.		005000	04/00/0000	Ocatal for ADO	04/40/0000	OIEEO!	4.0	
	1244590	CD19		01/09/2006	Control for 1D3	01/13/2006	GIFFOKA	10	
	1354706	CD19	BOUSQPF	01/12/2006	CXCL13 control experiment	01/13/2006	GIFFOKA	17	

Friday, March 10, 2006 Page 1 of 5

ID	Lot	Project	Requestor	Requested	Purpose	Delivered	Dispenser	Amt(mg)
								27
104	A-846889.	.0 8C11-1E10						
	1299103	ANTI-TNF ALPHA	MATHISL	02/07/2006	CIA-143 pos. control	02/08/2006	SWENSJT	22
	1299103	ANTI-TNF ALPHA	HUELSRM	12/01/2005	testing in asthma model	12/01/2005	HUELSR	12
	1299103	ANTI-TNF ALPHA	HUBBASN	02/02/2006	IL-13 4.54mg/ml concentration, three 1 ml vials	02/03/2006	PEREILX	12
	1299103	ANTI-TNF ALPHA	BUTLEDH	01/12/2006		01/16/2006	PEREILX	12
	1299103	ANTI-TNF ALPHA	NELSOCM	01/09/2006		01/06/2006	PEREILX	75
	1299103	ANTI-TNF ALPHA	BUTLEDH	02/09/2006	p38 project	02/10/2006	PEREILX	12
	1299103	ANTI-TNF ALPHA	HUELSRM	12/14/2005	PK and RAHA/MAMA	12/22/2005	HUELSR	4
	1299103	ANTI-TNF ALPHA	BARLOEH	02/16/2006	anti-id immunogen	02/17/2006	PEREILX	5
								154
136	A-850651.							
	1251319	ANTI-IL-12 (BACKUP)	WISCHEM	03/06/2006	in vitro bioassay	03/07/2006	GIFFOKA	0.5
								0.5
94	A-850652.	.0 IL-12 hu						
	1251320	ANTI IL-12 (BD ILS999)	GIFFOKA	02/06/2006	Requested by Brockman of Germany: PK-ELISA	02/06/2006	GIFFOKA	5
	1339493	ANTI IL-12 (BD ILS999)	GIFFOKA	02/06/2006	Binding Ability for the week of 02/06/06	02/09/2006	GIFFOKA	0.454
								5.454
33	A-864849.	.0 recombinant hIL-1a						
	1328996	ANTI IL-1 ALPHA/BETA	PEREILX	12/07/2005	Biotinylation	12/07/2005	PEREILX	1
								1
129	A-867085.	.0 1B7.11 mu lgG1						
	1309591	ANTI IL-1 ALPHA/BETA	HUBBASN	02/24/2006	IL-13 induced asthma model	02/24/2006	HUELSR	8
	1309591	ANTI IL-1 ALPHA/BETA	HUBBASN	02/06/2006	Control for in vivo astma model	02/06/2006	HUELSR	5.5
								13.5
130	A-899077.	.0 C17.8 ra IgG2a WT						
	1313096	ANTI IL-12 (BD ILS999)	ZHONGSX	03/01/2006	mIL23 MAb counter screening	03/02/2006	GIFFOKA	6
	1313096	ANTI IL-12 (BD ILS999)	WISCHEM	02/23/2006	In vitro IL-23 Bio-assay	02/24/2006	GIFFOKA	0.5
	1313096	ANTI IL-12 (BD ILS999)	CLABBAX	01/10/2006	Biacore testing	01/11/2006	GIFFOKA	0.1
								6.6
133	A-901968.	.0 Enbrel (Etanercept)						3.0
	1316937	ANTI-TNF ALPHA	KALGHLK	03/06/2006	MOA studies	03/08/2006	PEREILX	25
	v. March 10.	0000						Page 2 of 5

Friday, March 10, 2006 Page 2 of 5

ID	Lot	Project	Requestor	Requested	Purpose	Delivered	Dispenser	Amt(mg)
	1316937	ANTI-TNF ALPHA	PEREILX	01/26/2006	Large-scale F(ab) generation	02/10/2006	PEREILX	20
	1316937	ANTI-TNF ALPHA	BAJARAC	12/12/2005	IL-1ab	12/19/2005	PEREILX	0.5
								45.5
116	A-901969.	0 Remicade (Infliximab)						
	1316939	ANTI-TNF ALPHA	PEREILX	02/10/2006	F(ab) generation-Large Scale	02/14/2006	PEREILX	20
	1326524	ANTI-TNF ALPHA	BAJARAC	12/12/2005	IL-1ab	12/19/2005	PEREILX	0.5
								20.5
40	A-903701.	0 MAB210 mu IgG1/K wt						
	1319586	ANTI-TNF ALPHA	PEREILX	12/14/2005	D2E7 MOA-RBA method development	12/19/2005	PEREILX	8.42
								8.42
131	A-905245.	0 Recombinant Human IL-	13 Wt (213-I	L/CF)				
	1363379	ANTI IL-13	PEREILX	03/01/2006	Biacore evaluation	03/02/2006	HUELSR	0.2
	1363379	ANTI IL-13	BOSESX	03/03/2006	For Biacore testing of 4 different antibodies	03/07/2006	HUELSR	1
								1.2
73	A-920646.	0 recombinant mIL-1 alpha	ì					
	1342907	ANTI IL-1 ALPHA/BETA	HUELSRM	01/16/2006	Binding study for Mu anti IL-1a,b DVD4-IG	01/17/2006	PEREILX	0.03
								0.03
72	A-920647.	0 recombinant mIL-1 beta						
	1342908	ANTI IL-1 ALPHA/BETA	HUELSRM	01/16/2006	Binding study for Mu anti IL-1a,b DVD4-IG	01/17/2006	PEREILX	0.03
								0.03
29	A-926610.	0 TACI mlgG2a fusion						
	1350410	CD19	HUELSRM	12/01/2005	in vivo studies	12/01/2005	HUELSR	2
	1350410	CD19	GIFFOKA	01/18/2006	SEC Re-assay & compare w/ RH 07/20/05 run.	01/18/2006	GIFFOKA	65
								67
42	A-927819.	0 Y61 hu lgG1/L						
	1351888	ANTI-IL-12 (BACKUP)	GIFFOKA	12/14/2005	Postive control for IL-1ab experiment.	01/11/2006	GIFFOKA	0.2
								0.2
95	A-928040.	0 hu CXCL13/BLC/BCA-1						
	1352164	CXCL13	MANKOJA	02/06/2006	SDS-PAGE standard for Western Blots	02/06/2006	GIFFOKA	0.1
	1352164	CXCL13	ADAIRRM	02/02/2006	ligand for FLIPR assays	02/08/2006	GIFFOKA	0.3
								0.4
126	A-928046.	0 mu CXCL13/BLC/BCA-1						

Friday, March 10, 2006 Page 3 of 5

ID	Lot	Project	Requestor	Requested	Purpose	Delivered	Dispenser	Amt(mg)
	1352174	CXCL13	CLABBAX	02/23/2006	Biacore testing	02/23/2006	GIFFOKA	0.1
	1352174	CXCL13	BOUSQPF	01/18/2006	cxcl13 methods development	01/18/2006	GIFFOKA	0.1
	1352174	CXCL13	ADAIRRM	01/26/2006	ligand for chemotaxis and FLIPR experiments	01/26/2006	GIFFOKA	0.2
	1352174	CXCL13	ADAIRRM	02/02/2006	ligand for chemotaxis and FLIPR assays	02/08/2006	GIFFOKA	0.3
								0.7
117	A-928623	.0 SZ26-13C5.1A9						
	1369582	ANTI IL-13	GUJX	02/13/2006	V region sequencing by MS	02/16/2006	HUELSR	2
	1369582	ANTI IL-13	MILLERX	02/17/2006	A549 Bioassay/BIAcore	02/22/2006	HUELSR	0.2
	1369582	ANTI IL-13	MILLERX	03/01/2006	BIAcore Receptor Binding Studies	03/06/2006	HUELSR	0.5
	1369582	ANTI IL-13	WALLACX	01/26/2006	in-vivo asthma model	01/27/2006	HUELSR	10
								12.7
137	A-930993	.0 D2E7 F(ab¿)2						
	1355961	ANTI-TNF ALPHA	SCESNSM	03/08/2006	D2E7 MOA	03/09/2006	PEREILX	1
								1
93	A-931300	.0 SZ26-9C11.3F6.3B12						
	1369583	ANTI IL-13	WALLACX	02/03/2006	Asthma model	02/06/2006	HUELSR	10
	1369583	ANTI IL-13	MILLERX	02/17/2006	A549 Bioassay/BIAcore	02/22/2006	HUELSR	0.2
	1369583	ANTI IL-13		02/24/2006	IL-13 induced Asthma Model	02/24/2006	HUELSR	10
								20.2
139	A-931901	.0 C340 hu IgG1/K wt						20.2
	1372620	ANTI-IL-12 (BACKUP)	BAJARAC	03/08/2006	IL-12	03/08/2006	GIFFOKA	0.53
		,						0.53
63	A-932787.	.0 XW25-2C4-4H8 Mu IgG	1/K wt					0.55
00	1366530	CXCL13		01/11/2006	In vivo immune response studies	01/11/2006	GIFFOKA	10
	1366530	CXCL13		01/17/2006		01/16/2006	GIFFOKA	1.547
	1366530	CXCL13		02/14/2006	Fab generation	02/15/2006	GIFFOKA	3
	1366530	CXCL13		02/02/2006	Fab generation	02/02/2006	GIFFOKA	3
	1366530	CXCL13		02/09/2006	Biacore testing	02/08/2006	SWENSJT	0.1
	1366530	CXCL13		01/11/2006	CXCL13 assay development	01/12/2006	PEREILX	2
	1000000	0,102.10	20004.1	01/11/2000	excelle accay development	01/12/2000	· Littereyt	19.647
110	A-932797	.0 XW25-6A2-2F10 Mu Ig0	21/k wt					19.647
110	1366521	CXCL13		02/09/2006	Biacore testing	02/08/2006	SWENSJT	0.1
	1366521	CXCL13	_	01/11/2006	In vivo immune response studies	01/11/2006	GIFFOKA	10
			0010007	. 51/11/2000	iii vivo iiiiiidilo response studies	01/11/2000		
Frida	y, March 10,	2006					I	Page 4 of 5

Friday, March 10, 2006 Page 4 of 5

ID	Lot	Project	Requestor	Requested	Purpose	Delivered	Dispenser	Amt(mg)
	1366521	CXCL13	ADAIRRM	01/17/2006		01/16/2006	GIFFOKA	1.1
	1366521	CXCL13	BOUSQPF	01/11/2006	CXCL13 methods development	01/12/2006	PEREILX	1.5
					·			12.7
122	A-933162.	0 8C11-1E10 F(ab')2						
	1358767	ANTI-TNF ALPHA	BARLOEH	02/16/2006	Anti-id immunogen	02/24/2006	PEREILX	1
								1
138	A-937316.	0 1D4.7 hu lgG1 mut (234	235)/K					
	1372619	ANTI-IL-12 (BACKUP)	BAJARAC	03/08/2006	IL-12	03/08/2006	GIFFOKA	0.63
								0.63
96	A-939093.	0 11B11.2D2						
	1366541	ANTI IL-13	HUELSRM	02/06/2006	SEC purification to remove aggragates	02/06/2006	HUELSR	22.2768
								22.2768
52	A-940174.	0 Recombinant Murine IL-	23					
	1367752	IMMUNOSCIENCE EXPLO	ZHONGSX	01/06/2006	immunization	01/11/2006	GIFFOKA	2
	1367752	IMMUNOSCIENCE EXPLO	QUINTLJ	01/10/2006	splenocyte assay	01/11/2006	GIFFOKA	0.1
	1367752	IMMUNOSCIENCE EXPLO	CLABBAX	01/10/2006	Biacore testing	01/11/2006	GIFFOKA	0.1
	1367752	IMMUNOSCIENCE EXPLO	CLABBAX	01/30/2006	Biacore testing	01/30/2006	GIFFOKA	0.1
	1367752	IMMUNOSCIENCE EXPLO	ZHONGSX	01/06/2006	immunization	01/06/2006	GIFFOKA	2
	1367752	IMMUNOSCIENCE EXPLO	QUINNCM	01/13/2006	biotinylation	01/12/2006	PEREILX	1
								5.3
57	A-940175.	0 Recombinant Human IL-	23					
	1367754	IMMUNOSCIENCE EXPLO	CLABBAX	01/10/2006	Biacore testing	01/11/2006	GIFFOKA	0.1
	1367754	IMMUNOSCIENCE EXPLO	QUINTLJ	01/10/2006	splenocyte assay	01/11/2006	GIFFOKA	0.1
	1367754	IMMUNOSCIENCE EXPLO	CLABBAX	02/08/2006	Biacore testing	02/08/2006	GIFFOKA	0.1
								0.3

Friday, March 10, 2006 Page 5 of 5

This document was created with Win2PDF available at http://www.daneprairie.com. The unregistered version of Win2PDF is for evaluation or non-commercial use only.